nodes	percent_of_prediction	percent_of_DWPC	metapath
Trabectedin—CYP2C9—Leflunomide—systemic scleroderma	0.094	0.338	CbGbCtD
Trabectedin—CYP2D6—Captopril—systemic scleroderma	0.0674	0.243	CbGbCtD
Trabectedin—CYP2C19—Prednisone—systemic scleroderma	0.0558	0.201	CbGbCtD
Trabectedin—CYP2C9—cardial valve—systemic scleroderma	0.0401	0.288	CbGeAlD
Trabectedin—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0338	0.121	CbGbCtD
Trabectedin—CYP3A4—Prednisone—systemic scleroderma	0.027	0.0971	CbGbCtD
Trabectedin—SRC—artery—systemic scleroderma	0.0147	0.106	CbGeAlD
Trabectedin—SRC—endothelium—systemic scleroderma	0.0124	0.0893	CbGeAlD
Trabectedin—SRC—blood vessel—systemic scleroderma	0.0115	0.0823	CbGeAlD
Trabectedin—SRC—connective tissue—systemic scleroderma	0.00587	0.0422	CbGeAlD
Trabectedin—PTGS1—artery—systemic scleroderma	0.00549	0.0394	CbGeAlD
Trabectedin—SRC—smooth muscle tissue—systemic scleroderma	0.00537	0.0386	CbGeAlD
Trabectedin—SRC—skin of body—systemic scleroderma	0.0053	0.0381	CbGeAlD
Trabectedin—PTGS1—endothelium—systemic scleroderma	0.00464	0.0333	CbGeAlD
Trabectedin—PTGS1—blood vessel—systemic scleroderma	0.00428	0.0307	CbGeAlD
Trabectedin—SRC—digestive system—systemic scleroderma	0.00424	0.0305	CbGeAlD
Trabectedin—SRC—TSLP Signaling Pathway—TNFSF4—systemic scleroderma	0.0041	0.0408	CbGpPWpGaD
Trabectedin—SRC—FCGR activation—CD247—systemic scleroderma	0.00399	0.0397	CbGpPWpGaD
Trabectedin—SRC—Signaling events mediated by focal adhesion kinase—GIT2—systemic scleroderma	0.00374	0.0372	CbGpPWpGaD
Trabectedin—SRC—lung—systemic scleroderma	0.00354	0.0255	CbGeAlD
Trabectedin—SRC—Rac1/Pak1/p38/MMP-2 pathway—TNIP1—systemic scleroderma	0.00309	0.0307	CbGpPWpGaD
Trabectedin—SRC—Integrin-mediated Cell Adhesion—GIT2—systemic scleroderma	0.00252	0.025	CbGpPWpGaD
Trabectedin—SRC—Integrin alphaIIb beta3 signaling—CSK—systemic scleroderma	0.00237	0.0235	CbGpPWpGaD
Trabectedin—CYP2C19—digestive system—systemic scleroderma	0.00224	0.0161	CbGeAlD
Trabectedin—PTGS1—connective tissue—systemic scleroderma	0.00219	0.0158	CbGeAlD
Trabectedin—SRC—Glypican 1 network—BLK—systemic scleroderma	0.00212	0.0211	CbGpPWpGaD
Trabectedin—SRC—Ephrin B reverse signaling—BLK—systemic scleroderma	0.00212	0.0211	CbGpPWpGaD
Trabectedin—PTGS1—smooth muscle tissue—systemic scleroderma	0.00201	0.0144	CbGeAlD
Trabectedin—SRC—CTLA4 inhibitory signaling—CTLA4—systemic scleroderma	0.00199	0.0198	CbGpPWpGaD
Trabectedin—PTGS1—skin of body—systemic scleroderma	0.00198	0.0142	CbGeAlD
Trabectedin—SRC—Signaling events mediated by TCPTP—CSF1—systemic scleroderma	0.00196	0.0195	CbGpPWpGaD
Trabectedin—SRC—Alpha-synuclein signaling—BLK—systemic scleroderma	0.00184	0.0183	CbGpPWpGaD
Trabectedin—SRC—Regulation of p38-alpha and p38-beta—BLK—systemic scleroderma	0.00184	0.0183	CbGpPWpGaD
Trabectedin—SRC—Platelet Aggregation (Plug Formation)—CSK—systemic scleroderma	0.00184	0.0183	CbGpPWpGaD
Trabectedin—SRC—EPHA forward signaling—BLK—systemic scleroderma	0.00175	0.0174	CbGpPWpGaD
Trabectedin—CYP2C9—digestive system—systemic scleroderma	0.00173	0.0125	CbGeAlD
Trabectedin—CYP2E1—digestive system—systemic scleroderma	0.00164	0.0118	CbGeAlD
Trabectedin—SRC—Signaling events mediated by PTP1B—CSF1—systemic scleroderma	0.00159	0.0158	CbGpPWpGaD
Trabectedin—PTGS1—digestive system—systemic scleroderma	0.00158	0.0114	CbGeAlD
Trabectedin—CYP2E1—tendon—systemic scleroderma	0.00156	0.0112	CbGeAlD
Trabectedin—SRC—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—ITGAM—systemic scleroderma	0.00156	0.0155	CbGpPWpGaD
Trabectedin—PTGS1—tendon—systemic scleroderma	0.00151	0.0108	CbGeAlD
Trabectedin—SRC—Signaling events mediated by PTP1B—CSK—systemic scleroderma	0.0014	0.0139	CbGpPWpGaD
Trabectedin—CYP2E1—lung—systemic scleroderma	0.00137	0.00987	CbGeAlD
Trabectedin—SRC—Class I PI3K signaling events—BLK—systemic scleroderma	0.00137	0.0136	CbGpPWpGaD
Trabectedin—SRC—Integrins in angiogenesis—CSF1—systemic scleroderma	0.00136	0.0136	CbGpPWpGaD
Trabectedin—CYP3A4—digestive system—systemic scleroderma	0.00132	0.0095	CbGeAlD
Trabectedin—PTGS1—lung—systemic scleroderma	0.00132	0.0095	CbGeAlD
Trabectedin—CYP2D6—digestive system—systemic scleroderma	0.0013	0.00935	CbGeAlD
Trabectedin—PTGS1—Prostaglandin Synthesis and Regulation—EDN1—systemic scleroderma	0.00128	0.0128	CbGpPWpGaD
Trabectedin—SRC—TSLP Signaling Pathway—STAT4—systemic scleroderma	0.00126	0.0125	CbGpPWpGaD
Trabectedin—SRC—Integrins in angiogenesis—COL1A2—systemic scleroderma	0.00124	0.0124	CbGpPWpGaD
Trabectedin—SRC—Endothelins—COL1A2—systemic scleroderma	0.00124	0.0124	CbGpPWpGaD
Trabectedin—SRC—Signaling events mediated by PTP1B—BLK—systemic scleroderma	0.00122	0.0121	CbGpPWpGaD
Trabectedin—SRC—Thromboxane A2 receptor signaling—BLK—systemic scleroderma	0.00115	0.0114	CbGpPWpGaD
Trabectedin—SRC—Costimulation by the CD28 family—CSK—systemic scleroderma	0.00113	0.0112	CbGpPWpGaD
Trabectedin—SRC—Costimulation by the CD28 family—CD247—systemic scleroderma	0.00106	0.0106	CbGpPWpGaD
Trabectedin—SRC—CXCR4-mediated signaling events—RHOB—systemic scleroderma	0.00105	0.0104	CbGpPWpGaD
Trabectedin—SRC—Androgen receptor signaling pathway—RHOB—systemic scleroderma	0.001	0.00996	CbGpPWpGaD
Trabectedin—SRC—Cell surface interactions at the vascular wall—SELP—systemic scleroderma	0.000984	0.00979	CbGpPWpGaD
Trabectedin—SRC—CXCR4-mediated signaling events—CSK—systemic scleroderma	0.000954	0.0095	CbGpPWpGaD
Trabectedin—SRC—TGF-beta Signaling Pathway—SMAD7—systemic scleroderma	0.000943	0.00939	CbGpPWpGaD
Trabectedin—SRC—Fcgamma receptor (FCGR) dependent phagocytosis—CD247—systemic scleroderma	0.000923	0.00919	CbGpPWpGaD
Trabectedin—SRC—CXCR4-mediated signaling events—CD247—systemic scleroderma	0.000897	0.00893	CbGpPWpGaD
Trabectedin—SRC—Angiogenesis—NOS3—systemic scleroderma	0.000888	0.00884	CbGpPWpGaD
Trabectedin—SRC—CXCR4-mediated signaling events—BLK—systemic scleroderma	0.00083	0.00826	CbGpPWpGaD
Trabectedin—SRC—Integrin-mediated Cell Adhesion—CSK—systemic scleroderma	0.00083	0.00826	CbGpPWpGaD
Trabectedin—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.000821	0.0017	CcSEcCtD
Trabectedin—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.000818	0.0017	CcSEcCtD
Trabectedin—SRC—GAB1 signalosome—CSK—systemic scleroderma	0.000817	0.00813	CbGpPWpGaD
Trabectedin—Abdominal pain—Captopril—systemic scleroderma	0.000816	0.00169	CcSEcCtD
Trabectedin—Body temperature increased—Captopril—systemic scleroderma	0.000816	0.00169	CcSEcCtD
Trabectedin—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000813	0.00168	CcSEcCtD
Trabectedin—Oedema—Mycophenolic acid—systemic scleroderma	0.000812	0.00168	CcSEcCtD
Trabectedin—Anorexia—Leflunomide—systemic scleroderma	0.000811	0.00168	CcSEcCtD
Trabectedin—Nausea—Pentoxifylline—systemic scleroderma	0.000809	0.00168	CcSEcCtD
Trabectedin—Infection—Mycophenolic acid—systemic scleroderma	0.000806	0.00167	CcSEcCtD
Trabectedin—SRC—Costimulation by the CD28 family—CTLA4—systemic scleroderma	0.000805	0.00801	CbGpPWpGaD
Trabectedin—Diarrhoea—Mometasone—systemic scleroderma	0.000804	0.00167	CcSEcCtD
Trabectedin—Hypokalaemia—Prednisone—systemic scleroderma	0.000804	0.00167	CcSEcCtD
Trabectedin—Syncope—Lisinopril—systemic scleroderma	0.000803	0.00167	CcSEcCtD
Trabectedin—Leukopenia—Lisinopril—systemic scleroderma	0.000802	0.00166	CcSEcCtD
Trabectedin—Shock—Mycophenolic acid—systemic scleroderma	0.000799	0.00166	CcSEcCtD
Trabectedin—Alopecia—Mycophenolate mofetil—systemic scleroderma	0.000797	0.00165	CcSEcCtD
Trabectedin—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000796	0.00165	CcSEcCtD
Trabectedin—Hypotension—Leflunomide—systemic scleroderma	0.000795	0.00165	CcSEcCtD
Trabectedin—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.000795	0.00165	CcSEcCtD
Trabectedin—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.00079	0.00164	CcSEcCtD
Trabectedin—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000788	0.00163	CcSEcCtD
Trabectedin—SRC—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000787	0.00784	CbGpPWpGaD
Trabectedin—Loss of consciousness—Lisinopril—systemic scleroderma	0.000787	0.00163	CcSEcCtD
Trabectedin—SRC—Cell surface interactions at the vascular wall—ITGAM—systemic scleroderma	0.000786	0.00783	CbGpPWpGaD
Trabectedin—SRC—Senescence and Autophagy in Cancer—IRF5—systemic scleroderma	0.000785	0.00782	CbGpPWpGaD
Trabectedin—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000785	0.00163	CcSEcCtD
Trabectedin—Cough—Lisinopril—systemic scleroderma	0.000782	0.00162	CcSEcCtD
Trabectedin—SRC—Integrin-mediated Cell Adhesion—ITGAM—systemic scleroderma	0.00078	0.00777	CbGpPWpGaD
Trabectedin—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.000779	0.00162	CcSEcCtD
Trabectedin—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000778	0.00161	CcSEcCtD
Trabectedin—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000775	0.00161	CcSEcCtD
Trabectedin—Anorexia—Mycophenolic acid—systemic scleroderma	0.000774	0.0016	CcSEcCtD
Trabectedin—Insomnia—Leflunomide—systemic scleroderma	0.000769	0.0016	CcSEcCtD
Trabectedin—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.000769	0.00159	CcSEcCtD
Trabectedin—Paraesthesia—Leflunomide—systemic scleroderma	0.000764	0.00158	CcSEcCtD
Trabectedin—Arthralgia—Lisinopril—systemic scleroderma	0.000763	0.00158	CcSEcCtD
Trabectedin—Myalgia—Lisinopril—systemic scleroderma	0.000763	0.00158	CcSEcCtD
Trabectedin—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000759	0.00157	CcSEcCtD
Trabectedin—CYP2C19—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.000759	0.00756	CbGpPWpGaD
Trabectedin—Dyspnoea—Leflunomide—systemic scleroderma	0.000759	0.00157	CcSEcCtD
Trabectedin—Hypotension—Mycophenolic acid—systemic scleroderma	0.000758	0.00157	CcSEcCtD
Trabectedin—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000757	0.00157	CcSEcCtD
Trabectedin—Dyspepsia—Leflunomide—systemic scleroderma	0.000749	0.00155	CcSEcCtD
Trabectedin—Vomiting—Mometasone—systemic scleroderma	0.000747	0.00155	CcSEcCtD
Trabectedin—Rash—Mometasone—systemic scleroderma	0.000741	0.00154	CcSEcCtD
Trabectedin—Asthenia—Captopril—systemic scleroderma	0.000741	0.00154	CcSEcCtD
Trabectedin—Dermatitis—Mometasone—systemic scleroderma	0.00074	0.00153	CcSEcCtD
Trabectedin—Decreased appetite—Leflunomide—systemic scleroderma	0.00074	0.00153	CcSEcCtD
Trabectedin—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000739	0.00153	CcSEcCtD
Trabectedin—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000737	0.00153	CcSEcCtD
Trabectedin—Headache—Mometasone—systemic scleroderma	0.000736	0.00153	CcSEcCtD
Trabectedin—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000735	0.00152	CcSEcCtD
Trabectedin—Insomnia—Mycophenolic acid—systemic scleroderma	0.000734	0.00152	CcSEcCtD
Trabectedin—Fatigue—Leflunomide—systemic scleroderma	0.000734	0.00152	CcSEcCtD
Trabectedin—Oedema—Lisinopril—systemic scleroderma	0.000731	0.00152	CcSEcCtD
Trabectedin—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000729	0.00151	CcSEcCtD
Trabectedin—Constipation—Leflunomide—systemic scleroderma	0.000728	0.00151	CcSEcCtD
Trabectedin—Infection—Lisinopril—systemic scleroderma	0.000726	0.00151	CcSEcCtD
Trabectedin—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000725	0.0015	CcSEcCtD
Trabectedin—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000724	0.0015	CcSEcCtD
Trabectedin—Shock—Lisinopril—systemic scleroderma	0.000719	0.00149	CcSEcCtD
Trabectedin—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000716	0.00148	CcSEcCtD
Trabectedin—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000714	0.00148	CcSEcCtD
Trabectedin—Neutropenia—Prednisone—systemic scleroderma	0.000714	0.00148	CcSEcCtD
Trabectedin—SRC—Angiogenesis—MMP9—systemic scleroderma	0.000712	0.00709	CbGpPWpGaD
Trabectedin—Abdominal pain—Azathioprine—systemic scleroderma	0.000712	0.00148	CcSEcCtD
Trabectedin—Body temperature increased—Azathioprine—systemic scleroderma	0.000712	0.00148	CcSEcCtD
Trabectedin—Skin disorder—Lisinopril—systemic scleroderma	0.00071	0.00147	CcSEcCtD
Trabectedin—Diarrhoea—Captopril—systemic scleroderma	0.000706	0.00146	CcSEcCtD
Trabectedin—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000706	0.00146	CcSEcCtD
Trabectedin—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000704	0.00146	CcSEcCtD
Trabectedin—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000703	0.00146	CcSEcCtD
Trabectedin—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000701	0.00145	CcSEcCtD
Trabectedin—Fatigue—Mycophenolic acid—systemic scleroderma	0.0007	0.00145	CcSEcCtD
Trabectedin—CYP2D6—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.000698	0.00695	CbGpPWpGaD
Trabectedin—Nausea—Mometasone—systemic scleroderma	0.000698	0.00145	CcSEcCtD
Trabectedin—Anorexia—Lisinopril—systemic scleroderma	0.000697	0.00144	CcSEcCtD
Trabectedin—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000696	0.00144	CcSEcCtD
Trabectedin—SRC—PDGFR-beta signaling pathway—CSK—systemic scleroderma	0.000694	0.00691	CbGpPWpGaD
Trabectedin—Constipation—Mycophenolic acid—systemic scleroderma	0.000694	0.00144	CcSEcCtD
Trabectedin—Weight decreased—Prednisone—systemic scleroderma	0.000691	0.00143	CcSEcCtD
Trabectedin—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.00069	0.00143	CcSEcCtD
Trabectedin—SRC—TGF-beta Signaling Pathway—COL1A2—systemic scleroderma	0.000688	0.00685	CbGpPWpGaD
Trabectedin—SRC—Syndecan-2-mediated signaling events—MMP2—systemic scleroderma	0.000685	0.00682	CbGpPWpGaD
Trabectedin—Cough—Mycophenolate mofetil—systemic scleroderma	0.000685	0.00142	CcSEcCtD
Trabectedin—Hypotension—Lisinopril—systemic scleroderma	0.000683	0.00142	CcSEcCtD
Trabectedin—Dizziness—Captopril—systemic scleroderma	0.000683	0.00142	CcSEcCtD
Trabectedin—SRC—Endothelins—EDN1—systemic scleroderma	0.000673	0.0067	CbGpPWpGaD
Trabectedin—Abdominal pain—Leflunomide—systemic scleroderma	0.000673	0.00139	CcSEcCtD
Trabectedin—Body temperature increased—Leflunomide—systemic scleroderma	0.000673	0.00139	CcSEcCtD
Trabectedin—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000668	0.00139	CcSEcCtD
Trabectedin—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000668	0.00139	CcSEcCtD
Trabectedin—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000666	0.00138	CcSEcCtD
Trabectedin—Hypersensitivity—Azathioprine—systemic scleroderma	0.000664	0.00138	CcSEcCtD
Trabectedin—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000664	0.00138	CcSEcCtD
Trabectedin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000664	0.00138	CcSEcCtD
Trabectedin—SRC—Costimulation by the CD28 family—HLA-DQB1—systemic scleroderma	0.000663	0.0066	CbGpPWpGaD
Trabectedin—Insomnia—Lisinopril—systemic scleroderma	0.000661	0.00137	CcSEcCtD
Trabectedin—Paraesthesia—Lisinopril—systemic scleroderma	0.000656	0.00136	CcSEcCtD
Trabectedin—Vomiting—Captopril—systemic scleroderma	0.000656	0.00136	CcSEcCtD
Trabectedin—Dyspnoea—Lisinopril—systemic scleroderma	0.000652	0.00135	CcSEcCtD
Trabectedin—Rash—Captopril—systemic scleroderma	0.000651	0.00135	CcSEcCtD
Trabectedin—Dermatitis—Captopril—systemic scleroderma	0.00065	0.00135	CcSEcCtD
Trabectedin—Headache—Captopril—systemic scleroderma	0.000647	0.00134	CcSEcCtD
Trabectedin—Dyspepsia—Lisinopril—systemic scleroderma	0.000644	0.00133	CcSEcCtD
Trabectedin—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000642	0.00133	CcSEcCtD
Trabectedin—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000642	0.00133	CcSEcCtD
Trabectedin—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000641	0.00133	CcSEcCtD
Trabectedin—Infection—Mycophenolate mofetil—systemic scleroderma	0.000636	0.00132	CcSEcCtD
Trabectedin—Decreased appetite—Lisinopril—systemic scleroderma	0.000635	0.00132	CcSEcCtD
Trabectedin—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000631	0.00131	CcSEcCtD
Trabectedin—Fatigue—Lisinopril—systemic scleroderma	0.00063	0.00131	CcSEcCtD
Trabectedin—Shock—Mycophenolate mofetil—systemic scleroderma	0.00063	0.00131	CcSEcCtD
Trabectedin—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000628	0.0013	CcSEcCtD
Trabectedin—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000627	0.0013	CcSEcCtD
Trabectedin—Hypersensitivity—Leflunomide—systemic scleroderma	0.000627	0.0013	CcSEcCtD
Trabectedin—Constipation—Lisinopril—systemic scleroderma	0.000625	0.0013	CcSEcCtD
Trabectedin—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000622	0.00129	CcSEcCtD
Trabectedin—SRC—Plasma membrane estrogen receptor signaling—MMP2—systemic scleroderma	0.000617	0.00615	CbGpPWpGaD
Trabectedin—Diarrhoea—Azathioprine—systemic scleroderma	0.000616	0.00128	CcSEcCtD
Trabectedin—Haemoglobin—Prednisone—systemic scleroderma	0.000614	0.00127	CcSEcCtD
Trabectedin—Nausea—Captopril—systemic scleroderma	0.000613	0.00127	CcSEcCtD
Trabectedin—Haemorrhage—Prednisone—systemic scleroderma	0.000611	0.00127	CcSEcCtD
Trabectedin—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000611	0.00127	CcSEcCtD
Trabectedin—Asthenia—Leflunomide—systemic scleroderma	0.00061	0.00127	CcSEcCtD
Trabectedin—Pancytopenia—Methotrexate—systemic scleroderma	0.000606	0.00126	CcSEcCtD
Trabectedin—SRC—PDGFR-beta signaling pathway—BLK—systemic scleroderma	0.000604	0.00601	CbGpPWpGaD
Trabectedin—Connective tissue disorder—Prednisone—systemic scleroderma	0.000601	0.00124	CcSEcCtD
Trabectedin—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000599	0.00124	CcSEcCtD
Trabectedin—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000598	0.00124	CcSEcCtD
Trabectedin—Neutropenia—Methotrexate—systemic scleroderma	0.000597	0.00124	CcSEcCtD
Trabectedin—Dizziness—Azathioprine—systemic scleroderma	0.000596	0.00124	CcSEcCtD
Trabectedin—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000584	0.00121	CcSEcCtD
Trabectedin—Asthenia—Mycophenolic acid—systemic scleroderma	0.000582	0.00121	CcSEcCtD
Trabectedin—Diarrhoea—Leflunomide—systemic scleroderma	0.000582	0.00121	CcSEcCtD
Trabectedin—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000579	0.0012	CcSEcCtD
Trabectedin—SRC—Plasma membrane estrogen receptor signaling—NOS3—systemic scleroderma	0.000578	0.00576	CbGpPWpGaD
Trabectedin—Body temperature increased—Lisinopril—systemic scleroderma	0.000578	0.0012	CcSEcCtD
Trabectedin—Abdominal pain—Lisinopril—systemic scleroderma	0.000578	0.0012	CcSEcCtD
Trabectedin—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000575	0.00119	CcSEcCtD
Trabectedin—Vomiting—Azathioprine—systemic scleroderma	0.000573	0.00119	CcSEcCtD
Trabectedin—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000571	0.00118	CcSEcCtD
Trabectedin—Infestation—Methotrexate—systemic scleroderma	0.000569	0.00118	CcSEcCtD
Trabectedin—Infestation NOS—Methotrexate—systemic scleroderma	0.000569	0.00118	CcSEcCtD
Trabectedin—Rash—Azathioprine—systemic scleroderma	0.000568	0.00118	CcSEcCtD
Trabectedin—Dermatitis—Azathioprine—systemic scleroderma	0.000568	0.00118	CcSEcCtD
Trabectedin—Flushing—Prednisone—systemic scleroderma	0.000567	0.00118	CcSEcCtD
Trabectedin—SRC—Endothelins—MMP1—systemic scleroderma	0.000566	0.00563	CbGpPWpGaD
Trabectedin—Headache—Azathioprine—systemic scleroderma	0.000564	0.00117	CcSEcCtD
Trabectedin—SRC—EGF/EGFR Signaling Pathway—CSK—systemic scleroderma	0.000564	0.00562	CbGpPWpGaD
Trabectedin—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000564	0.00117	CcSEcCtD
Trabectedin—Dizziness—Leflunomide—systemic scleroderma	0.000563	0.00117	CcSEcCtD
Trabectedin—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000557	0.00115	CcSEcCtD
Trabectedin—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000555	0.00115	CcSEcCtD
Trabectedin—Stomatitis—Methotrexate—systemic scleroderma	0.000555	0.00115	CcSEcCtD
Trabectedin—Angiopathy—Prednisone—systemic scleroderma	0.000554	0.00115	CcSEcCtD
Trabectedin—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000553	0.00115	CcSEcCtD
Trabectedin—SRC—Oncostatin M Signaling Pathway—MMP1—systemic scleroderma	0.000552	0.00549	CbGpPWpGaD
Trabectedin—SRC—Glypican 1 network—TGFB1—systemic scleroderma	0.000551	0.00548	CbGpPWpGaD
Trabectedin—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000548	0.00114	CcSEcCtD
Trabectedin—SRC—Focal Adhesion—RHOB—systemic scleroderma	0.000545	0.00543	CbGpPWpGaD
Trabectedin—SRC—EPH-ephrin mediated repulsion of cells—MMP2—systemic scleroderma	0.000544	0.00542	CbGpPWpGaD
Trabectedin—Vomiting—Leflunomide—systemic scleroderma	0.000541	0.00112	CcSEcCtD
Trabectedin—Alopecia—Prednisone—systemic scleroderma	0.00054	0.00112	CcSEcCtD
Trabectedin—Hypersensitivity—Lisinopril—systemic scleroderma	0.000539	0.00112	CcSEcCtD
Trabectedin—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000538	0.00112	CcSEcCtD
Trabectedin—Dizziness—Mycophenolic acid—systemic scleroderma	0.000537	0.00111	CcSEcCtD
Trabectedin—Rash—Leflunomide—systemic scleroderma	0.000536	0.00111	CcSEcCtD
Trabectedin—Dermatitis—Leflunomide—systemic scleroderma	0.000536	0.00111	CcSEcCtD
Trabectedin—Mental disorder—Prednisone—systemic scleroderma	0.000535	0.00111	CcSEcCtD
Trabectedin—Nausea—Azathioprine—systemic scleroderma	0.000535	0.00111	CcSEcCtD
Trabectedin—Headache—Leflunomide—systemic scleroderma	0.000533	0.0011	CcSEcCtD
Trabectedin—Malnutrition—Prednisone—systemic scleroderma	0.000532	0.0011	CcSEcCtD
Trabectedin—Agranulocytosis—Methotrexate—systemic scleroderma	0.000531	0.0011	CcSEcCtD
Trabectedin—Asthenia—Lisinopril—systemic scleroderma	0.000525	0.00109	CcSEcCtD
Trabectedin—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000524	0.00109	CcSEcCtD
Trabectedin—SRC—Signaling by EGFR—CSK—systemic scleroderma	0.000521	0.00518	CbGpPWpGaD
Trabectedin—SRC—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	0.000517	0.00515	CbGpPWpGaD
Trabectedin—SRC—Signaling by EGFR in Cancer—CSK—systemic scleroderma	0.000516	0.00514	CbGpPWpGaD
Trabectedin—Vomiting—Mycophenolic acid—systemic scleroderma	0.000516	0.00107	CcSEcCtD
Trabectedin—SRC—Focal Adhesion—COL1A2—systemic scleroderma	0.000514	0.00512	CbGpPWpGaD
Trabectedin—Haemoglobin—Methotrexate—systemic scleroderma	0.000513	0.00106	CcSEcCtD
Trabectedin—Rash—Mycophenolic acid—systemic scleroderma	0.000512	0.00106	CcSEcCtD
Trabectedin—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000511	0.00106	CcSEcCtD
Trabectedin—Haemorrhage—Methotrexate—systemic scleroderma	0.000511	0.00106	CcSEcCtD
Trabectedin—Headache—Mycophenolic acid—systemic scleroderma	0.000508	0.00105	CcSEcCtD
Trabectedin—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000506	0.00105	CcSEcCtD
Trabectedin—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000506	0.00105	CcSEcCtD
Trabectedin—Nausea—Leflunomide—systemic scleroderma	0.000505	0.00105	CcSEcCtD
Trabectedin—Diarrhoea—Lisinopril—systemic scleroderma	0.0005	0.00104	CcSEcCtD
Trabectedin—Anaemia—Prednisone—systemic scleroderma	0.000492	0.00102	CcSEcCtD
Trabectedin—Dizziness—Lisinopril—systemic scleroderma	0.000483	0.001	CcSEcCtD
Trabectedin—SRC—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	0.000483	0.00481	CbGpPWpGaD
Trabectedin—Nausea—Mycophenolic acid—systemic scleroderma	0.000482	0.000999	CcSEcCtD
Trabectedin—Syncope—Prednisone—systemic scleroderma	0.000477	0.000989	CcSEcCtD
Trabectedin—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000472	0.000978	CcSEcCtD
Trabectedin—Loss of consciousness—Prednisone—systemic scleroderma	0.000468	0.000969	CcSEcCtD
Trabectedin—SRC—Focal Adhesion—ITGAM—systemic scleroderma	0.000467	0.00465	CbGpPWpGaD
Trabectedin—Vomiting—Lisinopril—systemic scleroderma	0.000465	0.000964	CcSEcCtD
Trabectedin—SRC—Plasma membrane estrogen receptor signaling—MMP9—systemic scleroderma	0.000464	0.00462	CbGpPWpGaD
Trabectedin—Angiopathy—Methotrexate—systemic scleroderma	0.000463	0.000961	CcSEcCtD
Trabectedin—Rash—Lisinopril—systemic scleroderma	0.000461	0.000956	CcSEcCtD
Trabectedin—Dermatitis—Lisinopril—systemic scleroderma	0.000461	0.000955	CcSEcCtD
Trabectedin—Mediastinal disorder—Methotrexate—systemic scleroderma	0.00046	0.000954	CcSEcCtD
Trabectedin—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.00046	0.000953	CcSEcCtD
Trabectedin—Headache—Lisinopril—systemic scleroderma	0.000458	0.000949	CcSEcCtD
Trabectedin—SRC—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—MMP9—systemic scleroderma	0.000455	0.00453	CbGpPWpGaD
Trabectedin—Myalgia—Prednisone—systemic scleroderma	0.000453	0.000939	CcSEcCtD
Trabectedin—Arthralgia—Prednisone—systemic scleroderma	0.000453	0.000939	CcSEcCtD
Trabectedin—Alopecia—Methotrexate—systemic scleroderma	0.000451	0.000936	CcSEcCtD
Trabectedin—SRC—Thromboxane A2 receptor signaling—NOS3—systemic scleroderma	0.000451	0.00449	CbGpPWpGaD
Trabectedin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.00045	0.000932	CcSEcCtD
Trabectedin—SRC—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	0.000449	0.00447	CbGpPWpGaD
Trabectedin—SRC—Oncostatin M Signaling Pathway—CCL2—systemic scleroderma	0.000449	0.00447	CbGpPWpGaD
Trabectedin—Mental disorder—Methotrexate—systemic scleroderma	0.000447	0.000928	CcSEcCtD
Trabectedin—SRC—Senescence and Autophagy in Cancer—IL1A—systemic scleroderma	0.000445	0.00443	CbGpPWpGaD
Trabectedin—Malnutrition—Methotrexate—systemic scleroderma	0.000445	0.000922	CcSEcCtD
Trabectedin—SRC—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	0.00044	0.00438	CbGpPWpGaD
Trabectedin—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000438	0.000909	CcSEcCtD
Trabectedin—Dysgeusia—Methotrexate—systemic scleroderma	0.000435	0.000903	CcSEcCtD
Trabectedin—Nausea—Lisinopril—systemic scleroderma	0.000434	0.0009	CcSEcCtD
Trabectedin—Oedema—Prednisone—systemic scleroderma	0.000434	0.0009	CcSEcCtD
Trabectedin—SRC—LPA receptor mediated events—MMP2—systemic scleroderma	0.000432	0.0043	CbGpPWpGaD
Trabectedin—SRC—Focal Adhesion—BLK—systemic scleroderma	0.000432	0.0043	CbGpPWpGaD
Trabectedin—Infection—Prednisone—systemic scleroderma	0.000431	0.000894	CcSEcCtD
Trabectedin—Back pain—Methotrexate—systemic scleroderma	0.00043	0.000892	CcSEcCtD
Trabectedin—Shock—Prednisone—systemic scleroderma	0.000427	0.000886	CcSEcCtD
Trabectedin—Nervous system disorder—Prednisone—systemic scleroderma	0.000426	0.000883	CcSEcCtD
Trabectedin—SRC—Syndecan-2-mediated signaling events—TGFB1—systemic scleroderma	0.000424	0.00422	CbGpPWpGaD
Trabectedin—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000424	0.000878	CcSEcCtD
Trabectedin—SRC—AGE/RAGE pathway—MMP2—systemic scleroderma	0.000422	0.0042	CbGpPWpGaD
Trabectedin—Skin disorder—Prednisone—systemic scleroderma	0.000422	0.000874	CcSEcCtD
Trabectedin—Anorexia—Prednisone—systemic scleroderma	0.000414	0.000858	CcSEcCtD
Trabectedin—Anaemia—Methotrexate—systemic scleroderma	0.000411	0.000852	CcSEcCtD
Trabectedin—SRC—EPH-ephrin mediated repulsion of cells—MMP9—systemic scleroderma	0.000409	0.00407	CbGpPWpGaD
Trabectedin—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000407	0.000844	CcSEcCtD
Trabectedin—Rash—Mycophenolate mofetil—systemic scleroderma	0.000404	0.000837	CcSEcCtD
Trabectedin—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000403	0.000836	CcSEcCtD
Trabectedin—Headache—Mycophenolate mofetil—systemic scleroderma	0.000401	0.000832	CcSEcCtD
Trabectedin—Leukopenia—Methotrexate—systemic scleroderma	0.000398	0.000825	CcSEcCtD
Trabectedin—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000396	0.00082	CcSEcCtD
Trabectedin—SRC—AGE/RAGE pathway—NOS3—systemic scleroderma	0.000395	0.00393	CbGpPWpGaD
Trabectedin—SRC—Cell surface interactions at the vascular wall—MMP1—systemic scleroderma	0.000394	0.00392	CbGpPWpGaD
Trabectedin—Insomnia—Prednisone—systemic scleroderma	0.000393	0.000814	CcSEcCtD
Trabectedin—Paraesthesia—Prednisone—systemic scleroderma	0.00039	0.000808	CcSEcCtD
Trabectedin—Cough—Methotrexate—systemic scleroderma	0.000388	0.000804	CcSEcCtD
Trabectedin—SRC—Signaling events mediated by VEGFR1 and VEGFR2—NOS3—systemic scleroderma	0.000386	0.00384	CbGpPWpGaD
Trabectedin—Dyspepsia—Prednisone—systemic scleroderma	0.000382	0.000792	CcSEcCtD
Trabectedin—Nausea—Mycophenolate mofetil—systemic scleroderma	0.00038	0.000789	CcSEcCtD
Trabectedin—Arthralgia—Methotrexate—systemic scleroderma	0.000379	0.000785	CcSEcCtD
Trabectedin—Myalgia—Methotrexate—systemic scleroderma	0.000379	0.000785	CcSEcCtD
Trabectedin—Decreased appetite—Prednisone—systemic scleroderma	0.000377	0.000782	CcSEcCtD
Trabectedin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000376	0.000779	CcSEcCtD
Trabectedin—SRC—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—TGFB1—systemic scleroderma	0.000375	0.00373	CbGpPWpGaD
Trabectedin—Fatigue—Prednisone—systemic scleroderma	0.000374	0.000776	CcSEcCtD
Trabectedin—SRC—FGF signaling pathway—MMP9—systemic scleroderma	0.000372	0.00371	CbGpPWpGaD
Trabectedin—Constipation—Prednisone—systemic scleroderma	0.000371	0.00077	CcSEcCtD
Trabectedin—PTGS1—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.00037	0.00369	CbGpPWpGaD
Trabectedin—SRC—Interleukin-11 Signaling Pathway—TGFB1—systemic scleroderma	0.000361	0.0036	CbGpPWpGaD
Trabectedin—Infection—Methotrexate—systemic scleroderma	0.00036	0.000747	CcSEcCtD
Trabectedin—SRC—Leptin signaling pathway—NOS3—systemic scleroderma	0.000357	0.00355	CbGpPWpGaD
Trabectedin—Nervous system disorder—Methotrexate—systemic scleroderma	0.000356	0.000738	CcSEcCtD
Trabectedin—SRC—Axon guidance—RHOB—systemic scleroderma	0.000356	0.00354	CbGpPWpGaD
Trabectedin—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000355	0.000737	CcSEcCtD
Trabectedin—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000355	0.000736	CcSEcCtD
Trabectedin—Skin disorder—Methotrexate—systemic scleroderma	0.000352	0.000731	CcSEcCtD
Trabectedin—SRC—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	0.000349	0.00347	CbGpPWpGaD
Trabectedin—Anorexia—Methotrexate—systemic scleroderma	0.000346	0.000717	CcSEcCtD
Trabectedin—Body temperature increased—Prednisone—systemic scleroderma	0.000343	0.000712	CcSEcCtD
Trabectedin—Abdominal pain—Prednisone—systemic scleroderma	0.000343	0.000712	CcSEcCtD
Trabectedin—Hypotension—Methotrexate—systemic scleroderma	0.000339	0.000703	CcSEcCtD
Trabectedin—SRC—IL-3 Signaling Pathway—TGFB1—systemic scleroderma	0.000332	0.0033	CbGpPWpGaD
Trabectedin—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000331	0.000685	CcSEcCtD
Trabectedin—Insomnia—Methotrexate—systemic scleroderma	0.000328	0.00068	CcSEcCtD
Trabectedin—Paraesthesia—Methotrexate—systemic scleroderma	0.000326	0.000675	CcSEcCtD
Trabectedin—SRC—LPA receptor mediated events—MMP9—systemic scleroderma	0.000325	0.00323	CbGpPWpGaD
Trabectedin—Dyspnoea—Methotrexate—systemic scleroderma	0.000324	0.000671	CcSEcCtD
Trabectedin—Hypersensitivity—Prednisone—systemic scleroderma	0.00032	0.000663	CcSEcCtD
Trabectedin—Dyspepsia—Methotrexate—systemic scleroderma	0.000319	0.000662	CcSEcCtD
Trabectedin—SRC—EPH-Ephrin signaling—MMP2—systemic scleroderma	0.000318	0.00316	CbGpPWpGaD
Trabectedin—SRC—AGE/RAGE pathway—MMP9—systemic scleroderma	0.000317	0.00316	CbGpPWpGaD
Trabectedin—Decreased appetite—Methotrexate—systemic scleroderma	0.000315	0.000654	CcSEcCtD
Trabectedin—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000313	0.000649	CcSEcCtD
Trabectedin—SRC—TGF-beta Signaling Pathway—MMP1—systemic scleroderma	0.000313	0.00312	CbGpPWpGaD
Trabectedin—Fatigue—Methotrexate—systemic scleroderma	0.000313	0.000649	CcSEcCtD
Trabectedin—Asthenia—Prednisone—systemic scleroderma	0.000312	0.000646	CcSEcCtD
Trabectedin—SRC—Leptin signaling pathway—IL1B—systemic scleroderma	0.000304	0.00302	CbGpPWpGaD
Trabectedin—Diarrhoea—Prednisone—systemic scleroderma	0.000297	0.000616	CcSEcCtD
Trabectedin—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000297	0.000615	CcSEcCtD
Trabectedin—Dizziness—Prednisone—systemic scleroderma	0.000287	0.000595	CcSEcCtD
Trabectedin—Abdominal pain—Methotrexate—systemic scleroderma	0.000287	0.000595	CcSEcCtD
Trabectedin—Body temperature increased—Methotrexate—systemic scleroderma	0.000287	0.000595	CcSEcCtD
Trabectedin—PTGS1—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.000281	0.0028	CbGpPWpGaD
Trabectedin—Vomiting—Prednisone—systemic scleroderma	0.000276	0.000572	CcSEcCtD
Trabectedin—Rash—Prednisone—systemic scleroderma	0.000274	0.000568	CcSEcCtD
Trabectedin—Dermatitis—Prednisone—systemic scleroderma	0.000274	0.000567	CcSEcCtD
Trabectedin—Headache—Prednisone—systemic scleroderma	0.000272	0.000564	CcSEcCtD
Trabectedin—SRC—VEGFA-VEGFR2 Pathway—NOS3—systemic scleroderma	0.000268	0.00267	CbGpPWpGaD
Trabectedin—Hypersensitivity—Methotrexate—systemic scleroderma	0.000267	0.000554	CcSEcCtD
Trabectedin—SRC—Hemostasis—SELP—systemic scleroderma	0.000267	0.00266	CbGpPWpGaD
Trabectedin—SRC—CXCR4-mediated signaling events—MMP9—systemic scleroderma	0.000261	0.0026	CbGpPWpGaD
Trabectedin—Asthenia—Methotrexate—systemic scleroderma	0.00026	0.00054	CcSEcCtD
Trabectedin—Nausea—Prednisone—systemic scleroderma	0.000258	0.000535	CcSEcCtD
Trabectedin—SRC—Developmental Biology—RHOB—systemic scleroderma	0.000254	0.00253	CbGpPWpGaD
Trabectedin—SRC—Signaling by VEGF—NOS3—systemic scleroderma	0.000253	0.00252	CbGpPWpGaD
Trabectedin—SRC—Hemostasis—RHOB—systemic scleroderma	0.000249	0.00248	CbGpPWpGaD
Trabectedin—Diarrhoea—Methotrexate—systemic scleroderma	0.000248	0.000515	CcSEcCtD
Trabectedin—Dizziness—Methotrexate—systemic scleroderma	0.00024	0.000497	CcSEcCtD
Trabectedin—SRC—EPH-Ephrin signaling—MMP9—systemic scleroderma	0.000239	0.00238	CbGpPWpGaD
Trabectedin—SRC—Senescence and Autophagy in Cancer—IL1B—systemic scleroderma	0.000232	0.00231	CbGpPWpGaD
Trabectedin—Vomiting—Methotrexate—systemic scleroderma	0.000231	0.000478	CcSEcCtD
Trabectedin—Rash—Methotrexate—systemic scleroderma	0.000229	0.000474	CcSEcCtD
Trabectedin—Dermatitis—Methotrexate—systemic scleroderma	0.000229	0.000474	CcSEcCtD
Trabectedin—Headache—Methotrexate—systemic scleroderma	0.000227	0.000471	CcSEcCtD
Trabectedin—SRC—Hemostasis—CSK—systemic scleroderma	0.000227	0.00226	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000225	0.00224	CbGpPWpGaD
Trabectedin—Nausea—Methotrexate—systemic scleroderma	0.000216	0.000447	CcSEcCtD
Trabectedin—SRC—Hemostasis—ITGAM—systemic scleroderma	0.000213	0.00212	CbGpPWpGaD
Trabectedin—SRC—Adaptive Immune System—CSK—systemic scleroderma	0.000196	0.00195	CbGpPWpGaD
Trabectedin—SRC—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	0.000193	0.00192	CbGpPWpGaD
Trabectedin—SRC—Innate Immune System—ITGAM—systemic scleroderma	0.000192	0.00191	CbGpPWpGaD
Trabectedin—SRC—Innate Immune System—CD247—systemic scleroderma	0.000192	0.00191	CbGpPWpGaD
Trabectedin—SRC—Adaptive Immune System—CD247—systemic scleroderma	0.000184	0.00184	CbGpPWpGaD
Trabectedin—SRC—Senescence and Autophagy in Cancer—TGFB1—systemic scleroderma	0.00018	0.00179	CbGpPWpGaD
Trabectedin—SRC—Innate Immune System—TNFAIP3—systemic scleroderma	0.00018	0.00179	CbGpPWpGaD
Trabectedin—SRC—Signaling by SCF-KIT—MMP9—systemic scleroderma	0.000173	0.00172	CbGpPWpGaD
Trabectedin—SRC—Adaptive Immune System—BLK—systemic scleroderma	0.000171	0.0017	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.00017	0.0017	CbGpPWpGaD
Trabectedin—SRC—Disease—SMAD7—systemic scleroderma	0.000156	0.00155	CbGpPWpGaD
Trabectedin—SRC—TGF-beta Signaling Pathway—TGFB1—systemic scleroderma	0.00015	0.00149	CbGpPWpGaD
Trabectedin—SRC—Disease—TGFBI—systemic scleroderma	0.000143	0.00142	CbGpPWpGaD
Trabectedin—SRC—Adaptive Immune System—CTLA4—systemic scleroderma	0.00014	0.00139	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.00013	0.00129	CbGpPWpGaD
Trabectedin—SRC—Immune System—CSK—systemic scleroderma	0.000119	0.00118	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000118	0.00118	CbGpPWpGaD
Trabectedin—SRC—Axon guidance—MMP2—systemic scleroderma	0.000118	0.00118	CbGpPWpGaD
Trabectedin—SRC—Immune System—IRF5—systemic scleroderma	0.000117	0.00116	CbGpPWpGaD
Trabectedin—SRC—Adaptive Immune System—HLA-DQB1—systemic scleroderma	0.000115	0.00115	CbGpPWpGaD
Trabectedin—SRC—Disease—HSPG2—systemic scleroderma	0.000114	0.00113	CbGpPWpGaD
Trabectedin—SRC—Immune System—IRF8—systemic scleroderma	0.000112	0.00111	CbGpPWpGaD
Trabectedin—SRC—Immune System—ITGAM—systemic scleroderma	0.000112	0.00111	CbGpPWpGaD
Trabectedin—SRC—Immune System—CD247—systemic scleroderma	0.000112	0.00111	CbGpPWpGaD
Trabectedin—SRC—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	0.000112	0.00111	CbGpPWpGaD
Trabectedin—SRC—Disease—CSK—systemic scleroderma	0.00011	0.00109	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—SMAD7—systemic scleroderma	0.000109	0.00109	CbGpPWpGaD
Trabectedin—SRC—Adaptive Immune System—CD40LG—systemic scleroderma	0.000109	0.00108	CbGpPWpGaD
Trabectedin—SRC—Hemostasis—MMP1—systemic scleroderma	0.000107	0.00106	CbGpPWpGaD
Trabectedin—SRC—Immune System—TNFAIP3—systemic scleroderma	0.000105	0.00104	CbGpPWpGaD
Trabectedin—SRC—Immune System—BLK—systemic scleroderma	0.000103	0.00103	CbGpPWpGaD
Trabectedin—SRC—Disease—CD247—systemic scleroderma	0.000103	0.00103	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—HSPG2—systemic scleroderma	0.0001	0.000996	CbGpPWpGaD
Trabectedin—SRC—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	9.94e-05	0.000989	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	9.82e-05	0.000978	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	8.96e-05	0.000891	CbGpPWpGaD
Trabectedin—SRC—Axon guidance—MMP9—systemic scleroderma	8.88e-05	0.000884	CbGpPWpGaD
Trabectedin—SRC—Immune System—CTLA4—systemic scleroderma	8.47e-05	0.000844	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—RHOB—systemic scleroderma	8.44e-05	0.00084	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—MMP2—systemic scleroderma	8.43e-05	0.000839	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—HSPG2—systemic scleroderma	7.96e-05	0.000793	CbGpPWpGaD
Trabectedin—SRC—Hemostasis—NOS3—systemic scleroderma	7.75e-05	0.000771	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—CSK—systemic scleroderma	7.69e-05	0.000765	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—CTGF—systemic scleroderma	7.59e-05	0.000755	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—HSPG2—systemic scleroderma	7.48e-05	0.000745	CbGpPWpGaD
Trabectedin—SRC—Immune System—HLA-DQB1—systemic scleroderma	6.98e-05	0.000695	CbGpPWpGaD
Trabectedin—SRC—Immune System—IL1A—systemic scleroderma	6.63e-05	0.00066	CbGpPWpGaD
Trabectedin—SRC—Immune System—CD40LG—systemic scleroderma	6.59e-05	0.000656	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—MMP9—systemic scleroderma	6.34e-05	0.000631	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—HSPG2—systemic scleroderma	5.77e-05	0.000575	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—CTGF—systemic scleroderma	5.67e-05	0.000564	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—HSPG2—systemic scleroderma	5.31e-05	0.000528	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—HSPG2—systemic scleroderma	5.26e-05	0.000524	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—TGFB1—systemic scleroderma	5.22e-05	0.00052	CbGpPWpGaD
Trabectedin—SRC—Hemostasis—TGFB1—systemic scleroderma	5.12e-05	0.00051	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—CTGF—systemic scleroderma	4.37e-05	0.000435	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—EDN1—systemic scleroderma	4.31e-05	0.000429	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—CTGF—systemic scleroderma	4.02e-05	0.0004	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—CTGF—systemic scleroderma	3.99e-05	0.000397	CbGpPWpGaD
Trabectedin—SRC—Disease—NOS3—systemic scleroderma	3.75e-05	0.000373	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—HSPG2—systemic scleroderma	3.47e-05	0.000345	CbGpPWpGaD
Trabectedin—SRC—Immune System—IL1B—systemic scleroderma	3.46e-05	0.000344	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—NOS3—systemic scleroderma	3.3e-05	0.000329	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—CCL2—systemic scleroderma	2.95e-05	0.000293	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—CTGF—systemic scleroderma	2.63e-05	0.000262	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—NOS3—systemic scleroderma	2.63e-05	0.000261	CbGpPWpGaD
Trabectedin—SRC—Disease—TGFB1—systemic scleroderma	2.48e-05	0.000247	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—NOS3—systemic scleroderma	2.47e-05	0.000246	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—MMP9—systemic scleroderma	2.11e-05	0.00021	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—NOS3—systemic scleroderma	1.9e-05	0.00019	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—NOS3—systemic scleroderma	1.75e-05	0.000174	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—TGFB1—systemic scleroderma	1.74e-05	0.000173	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—NOS3—systemic scleroderma	1.74e-05	0.000173	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—NOS3—systemic scleroderma	1.14e-05	0.000114	CbGpPWpGaD
